Literature DB >> 12567300

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

Scott K Fridkin1, Jeff Hageman, Linda K McDougal, Jasmine Mohammed, William R Jarvis, Trish M Perl, Fred C Tenover.   

Abstract

Infections caused by Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS; minimum inhibitory concentration [MIC], >or=4 microg/mL), including vancomycin-intermediate S. aureus (VISA; MIC, 8 microg/mL), are a new clinical and public health dilemma. Prospective surveillance and a nested case-control study of patients in the United States infected with SA-RVS was conduced from March 1999 through December 2000. Control patients were persons infected with oxacillin-resistant S. aureus (MIC of vancomycin, <or=2 microg/mL). Among 19 case patients, 4 infections were due to VISA and 15 were due to non-VISA SA-RVS. Case patients with and those without VISA infection had similar clinical presentations and outcomes; the overall attributable mortality rate was 63%. Isolates recovered from case patients had heterogeneous pulsed-field gel electrophoresis banding patterns, regardless of the MIC of vancomycin. Neither dialysis nor chronic renal failure were predictive of case status compared with control status. Independent risk factors for being a case patient included antecedent vancomycin use and prior oxacillin-resistant S. aureus infection 2 or 3 months before the current infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12567300     DOI: 10.1086/346207

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  91 in total

1.  A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.

Authors:  Suttirak Chaiwongkarjohn; Pornpoj Pramyothin; Nuntra Suwantarat; Matthew J Bankowski; Terrie Koyamatsu; Steven E Seifried; Erlaine F Bello
Journal:  Hawaii Med J       Date:  2011-11

Review 2.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 3.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Foot Infections in Diabetic Patients.

Authors:  James S Tan
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

5.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

6.  Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children.

Authors:  Kanokporn Mongkolrattanothai; Robert S Daum
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 7.  Antibacterial resistance.

Authors:  Jocelyn Y Ang; Elias Ezike; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

8.  Clinical evaluation of the DiversiLab microbial typing system using repetitive-sequence-based PCR for characterization of Staphylococcus aureus strains.

Authors:  Cheryl K Shutt; June I Pounder; Sam R Page; Barbara J Schaecher; Gail L Woods
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).

Authors:  Preston Howard Blomquist
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 10.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.